How can we manage resistance to antiangiogenic drugs?

Clin Investig (Lond). 2014;4(6):483-486. doi: 10.4155/cli.14.46.
No abstract available

Keywords: CRLX101; HIF-1α; IL-17; angiogenesis; bevacizumab; drug resistance; neuropilin-1; preclinical models; predictive biomarkers; ramucirumab; β1-integrin.